Galderma’s breakthrough drug Nemluvio gains rapid FDA approval for severe itch condition
Galderma has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving Nemluvio (nemolizumab) for the treatment of prurigo nodularis in adults. This approval allows Nemluvio to be administered as a pre-filled pen for subcutaneous injection, providing a new option for patients suffering from this challenging condition. The drug’s approval follows its […]